Latest News
Kidney Care’s $2.5 Billion Timing Problem
Capital is flowing to the wrong point on the disease timeline Kidney care has attracted more than $2.5 billion in investment capital over the past five years. The amount tells a clear story. Unfortunately, it may be the wrong one. Investment has mostly concentrated on...
Latest News
Finding AF Before It Strikes: The Case for National Screening
There’s a concerning number of Australians living with a dangerous heart rhythm disorder - and many of them have no idea. Atrial fibrillation (AF) is a condition most people have never heard of and that’s a big problem, because it is already a silent cause of stroke. ...
Creative Biolabs Discusses Antibody Library Screening Workflow
Antibody library screening is widely used to identify antibody fragments, such as scFv, Fab, and single-domain antibodies, from large molecular repertoires. Compared with immunization-dependent approaches, library screening can be especially useful for challenging...
CAR-T Therapy Reaches Solid Tumours for the First Time
China's National Medical Products Administration (NMPA) approved satricabtagene autoleucel (satri-cel) on 22 June 2026, making it the world's first CAR-T cell therapy approved for a solid tumour. Developed by Shanghai-based CARsgen Therapeutics, satri-cel is cleared...
Late-Stage Obesity Drugs: 7 to Watch Beyond Ozempic
The weight-loss revolution that began with Ozempic and Wegovy is entering a more crowded and competitive phase, and the field of late-stage obesity drugs has become the most closely watched area in pharmaceutical research. Two recent milestones show how fast the...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
New Hope for Patients with Hereditary Hemorrhagic Telangiectasia
Engasertib Trial Offers New Hope for Patients with Hereditary Hemorrhagic Telangiectasia A recent clinical study has delivered encouraging results for people living with hereditary hemorrhagic telangiectasia, a rare genetic vascular disorder that causes chronic and...
ALS- Clinical Signals of a “Synaptic Regenerative” Approach!
Pharmaceutical approaches to ALS remain sparse and "hard-to-develop". Riluzole (approved 1995) and edaravone (IV in 2017, oral in 2022) only offer modest benefits. More recently, Biogen's Qalsody (tofersen) was approved for SOD1-mutant ALS. But a new wave of new...
Decision Frameworks in Pharma
Decision Frameworks in Pharma: From RAVE and DICE to Lilly’s Truth-Seeking Machine What Works, What Kills What, and Why It Matters In pharmaceutical R&D, where billions ride on the flip of a biological coin, decision frameworks aren’t just nice-to-haves - they’re...
Follow the Science? It Would Rather Follow a Leader… (2025 Update)
Eight years on from the first version of this article, “follow the science” is still the industry’s favourite comfort blanket. It sounds noble, unassailable, the kind of thing you put on a lab-wall poster next to a photo of Rosalind Franklin. (Following the X...
Durvalumab approved in the US
Durvalumab approved in the US as first & only perioperative immunotherapy for patients with early gastric & gastroesophageal cancers! The FDA approved Durvalumab (Imfinzi) in combination with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)...
Redefining Drug Safety: Global Regulators Push for AI and 3D Tissues
For decades, the laboratory rat has been the quintessential symbol of biomedical research. Yet, as 2025 draws to a close, a profound shift is reshaping the life sciences landscape. Global regulatory bodies are no longer merely encouraging alternatives to animal...
Novartis to Acquire Avidity in $12B RNA Therapy Deal
The biotech M&A boom shows no signs of slowing. Novartis has struck a definitive agreement to acquire Avidity Biosciences for US$12 billion in cash, marking one of the most consequential acquisitions in the RNA therapy space in recent years. The deal significantly...
Ground-Breaking Gene Therapy for Hunter Syndrome
Miraculous Progress for 3-Year-Old After Ground-Breaking Gene Therapy for Hunter Syndrome A three-year-old boy, Oliver Chu, has astounded doctors after becoming the first person in the world with Hunter syndrome also called MPS II to receive a pioneering gene therapy....
UK Drug Pricing Pressure Threatens Pharma Investment and Competitiveness
The row over drug pricing in the United Kingdom has escalated into a defining test for the government’s life sciences strategy. In 2025 tensions between Whitehall and major pharmaceutical companies have hardened, with a series of high-profile investment pauses and...
AstraZeneca and Sun Pharma Join Forces in India
AstraZeneca and Sun Pharma Join Forces to Expand Access to Hyperkalaemia Treatment in India In a major development for renal and cardiac care in India, AstraZeneca Pharma India and Sun Pharmaceutical Industries have announced a strategic co-marketing partnership to...
J&J Acquires Halda Therapeutics to Boost Oncology Pipeline
Johnson & Johnson has agreed to acquire Halda Therapeutics for $3.05 billion in cash, a transaction announced on 17 November 2025 and expected to close in the coming months, subject to customary regulatory approvals. Halda’s Novel RIPTAC Modality Halda...
The Future of Clinical Trials: Virtual, Decentralised, and Patient-Led
Clinical trials have long been the backbone of medical innovation, providing the evidence base for new treatments, diagnostics, and preventive measures. Yet for decades, the traditional model, site-based, paper-driven, and geographically limited, has been plagued by...
New Hope for Patients with Hereditary Hemorrhagic Telangiectasia
Engasertib Trial Offers New Hope for Patients with Hereditary Hemorrhagic Telangiectasia A recent clinical study has delivered encouraging results for people living with hereditary hemorrhagic telangiectasia, a rare genetic vascular disorder that causes chronic and...
ALS- Clinical Signals of a “Synaptic Regenerative” Approach!
Pharmaceutical approaches to ALS remain sparse and "hard-to-develop". Riluzole (approved 1995) and edaravone (IV in 2017, oral in 2022) only offer modest benefits. More recently, Biogen's Qalsody (tofersen) was approved for SOD1-mutant ALS. But a new wave of new...
Decision Frameworks in Pharma
Decision Frameworks in Pharma: From RAVE and DICE to Lilly’s Truth-Seeking Machine What Works, What Kills What, and Why It Matters In pharmaceutical R&D, where billions ride on the flip of a biological coin, decision frameworks aren’t just nice-to-haves - they’re...
Follow the Science? It Would Rather Follow a Leader… (2025 Update)
Eight years on from the first version of this article, “follow the science” is still the industry’s favourite comfort blanket. It sounds noble, unassailable, the kind of thing you put on a lab-wall poster next to a photo of Rosalind Franklin. (Following the X...
Durvalumab approved in the US
Durvalumab approved in the US as first & only perioperative immunotherapy for patients with early gastric & gastroesophageal cancers! The FDA approved Durvalumab (Imfinzi) in combination with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)...
Redefining Drug Safety: Global Regulators Push for AI and 3D Tissues
For decades, the laboratory rat has been the quintessential symbol of biomedical research. Yet, as 2025 draws to a close, a profound shift is reshaping the life sciences landscape. Global regulatory bodies are no longer merely encouraging alternatives to animal...
Novartis to Acquire Avidity in $12B RNA Therapy Deal
The biotech M&A boom shows no signs of slowing. Novartis has struck a definitive agreement to acquire Avidity Biosciences for US$12 billion in cash, marking one of the most consequential acquisitions in the RNA therapy space in recent years. The deal significantly...
Ground-Breaking Gene Therapy for Hunter Syndrome
Miraculous Progress for 3-Year-Old After Ground-Breaking Gene Therapy for Hunter Syndrome A three-year-old boy, Oliver Chu, has astounded doctors after becoming the first person in the world with Hunter syndrome also called MPS II to receive a pioneering gene therapy....
UK Drug Pricing Pressure Threatens Pharma Investment and Competitiveness
The row over drug pricing in the United Kingdom has escalated into a defining test for the government’s life sciences strategy. In 2025 tensions between Whitehall and major pharmaceutical companies have hardened, with a series of high-profile investment pauses and...
AstraZeneca and Sun Pharma Join Forces in India
AstraZeneca and Sun Pharma Join Forces to Expand Access to Hyperkalaemia Treatment in India In a major development for renal and cardiac care in India, AstraZeneca Pharma India and Sun Pharmaceutical Industries have announced a strategic co-marketing partnership to...
J&J Acquires Halda Therapeutics to Boost Oncology Pipeline
Johnson & Johnson has agreed to acquire Halda Therapeutics for $3.05 billion in cash, a transaction announced on 17 November 2025 and expected to close in the coming months, subject to customary regulatory approvals. Halda’s Novel RIPTAC Modality Halda...
The Future of Clinical Trials: Virtual, Decentralised, and Patient-Led
Clinical trials have long been the backbone of medical innovation, providing the evidence base for new treatments, diagnostics, and preventive measures. Yet for decades, the traditional model, site-based, paper-driven, and geographically limited, has been plagued by...
Featured Articles
Further News
Expansion at Oxford Science Park Boosts Innovation Ecosystem
The Oxford Science Park (OSP), located on the southern edge of Oxford and owned by Magdalen College, Oxford, is entering a significant new phase of expansion aimed at strengthening the UK’s life sciences and technology infrastructure. This growth is driven by strong...
Remote Stroke Surgery Breakthrough with New Robotic System
In a landmark development for stroke treatment, medical technology company Remedy Robotics has announced what it describes as the world’s first fully remote endovascular neurointerventional procedures using its N1 robotic system. The announcement, made on 6 October...
Bacterial Movement Beyond Flagella: Surprising New Mechanisms Uncovered
Emerging Evidence of Alternative Motility For decades, scientists have believed that bacterial movement relied almost entirely on the rotation of whip-like flagella, which propel cells through liquids or across surfaces. However, new research has revealed that some...
The Passing of a Scientific Giant: James D. Watson
Renowned molecular biologist James D. Watson has died at the age of 97, his son and the Cold Spring Harbor Laboratory (CSHL) in New York confirmed. The scientist, best known for co-discovering the double helix structure of DNA in 1953, passed away following a brief...
The Rise of Cell and Gene Therapy Hubs Across Northern England
The life sciences landscape in northern England is undergoing a dynamic evolution, driven by the growing importance of advanced therapies such as cell and gene treatments. These innovative approaches, which aim to treat or cure diseases by intervening at the level of...
Current Talent, Skills and Infrastructure in the Life Science Industry
The life science sector encompassing pharmaceuticals, biotechnology, medical technologies, diagnostics and related services is evolving rapidly. Success in this industry no longer rests solely on scientific discovery. Increasingly it depends on the right talent,...
Rewriting the MND Playbook
How AI and Biomarkers Are Accelerating the Fight Against Motor Neurone Disease Every ninety minutes in the United Kingdom, someone receives a diagnosis of Motor Neurone Disease (MND), also known as Amyotrophic Lateral Sclerosis (ALS), and every ninety minutes, someone...
Challenges in Life Sciences Real Estate
The commercial real estate market serving the life sciences industry is currently undergoing a complex period of adjustment. The underlying dynamics that once propelled rapid growth, such as enthusiastic venture capital, strong demand from biotech and pharmaceutical...
Age Related T Cell Changes Weaken Vaccine Response in Older People
As the population ages, one of the major challenges facing public health is that vaccines tend to become less effective in older adults. A growing body of research increasingly points to specific changes in T cells, critical components of the immune system, as a key...
First Malaria Treatment Approved for Babies and Young Children
A landmark milestone in global health has been reached as the antimalarial drug Coartem Baby has received approval from the Swiss regulator Swissmedic. It is the first treatment specifically designed for newborns and very young infants suffering from malaria. Bridging...
ProImmune Introduces ProVE SL Monomers to Boost T Cell Research
ProImmune has launched its new ProVE SL (Self-Loading) MHC Class I monomers, positioning these reagents as a next-generation tool for researchers studying antigen-specific CD8+ T cells. The announcement highlights the company’s aim to accelerate T cell research by...
Novo Nordisk Locks Horns with Pfizer in Late Bid for Metsera
Danish pharmaceutical leader Novo Nordisk has made a dramatic late entry into the takeover race for United States biotech Metsera, challenging Pfizer’s earlier agreement and sparking a fierce bidding war in one of the most competitive areas of the life sciences...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.